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bronchial anastomosis in terms of late com-
plications. Finally, the completeness of re-
section after lung-sparing resection in term
of extension of mediastinal and hilar lymph
node dissection was comparable to that ob-
tained after pneumonectomy. At present,
our experience with lung-sparing technique
for lung cancer after induction treatment
consists of 58 patients operated on through
a period of 5 years, and it represent 54% of
all sleeve resections performed during the
same period (n  106). A vascular resec-
tion was associated in 35% of cases. The
overall postoperative morbidity rate and
mortality of patients who underwent sleeve
resection were 34% and 4.7%, respec-
tively. Table 1 reports the comparison be-
tween the two groups (induction treatment
vs no treatment).
This recent updated experience con-
firms our previous results and strongly sup-
ports the result of the article of Ohta and
colleagues.1 Bronchoplastic resection after
induction chemotherapy is a safe treatment
for locally advanced lung cancer, and it
should be done whenever it is possible in-
stead of pneumonectomy.
G. Veronesi, MD
M. E. Leon
L. Spaggiari, MD, PhD
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Reply to the Editor:
My coauthors and I appreciate the com-
ments by Veronesi and colleagues from the
European Institute of Oncology. We find
their results1 to be consistent with ours,2
with their latest study reconfirming our
conclusion. They had excellent outcomes
with a sleeve resection after induction ther-
apy; however, the overall morbidity and
mortality resulting from a primary opera-
tion were 44% and 6%, respectively, which
were higher than those of Kutlu and Gold-
straw3 (12% and 2%, respectively), who
used the same continuous suture technique
for the bronchial anastomosis as did Vero-
nesi and colleagues.1 The somewhat high
morbidity rate in their control group may
have had an influence on the statistical
comparison analysis. Because surgical
complications had a correlation with the
extent of surgical resections,4 patients in
their study who underwent a primary oper-
ation have probably received a more radi-
cal dissection of the tumor and invaded
organs.
In our experience to date, the overall
surgical morbidity of 22 patients who re-
ceived preoperative induction therapy is
32% and that of 38 patients who underwent
a primary operation is 8%, and no postop-
erative deaths have occurred. Thus we be-
lieve that a sleeve resection is useful for
any patient with centrally located advanced
lung cancer in whom the anatomy is suit-
able for such a procedure. Further, we can
insist, and are supported by the results of
Veronesi and colleagues,2 that a sleeve re-
section is a safe alternative to pneumonec-
tomy, irrespective of preoperative treat-
ment.
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Lack of evidence for vitamin C as
acute vasodilator
To the Editor:
We read with interest the article by Drossos
and colleagues.1 They measured radial ar-
tery diameter before and after acute oral
administration of vitamin C (2 g) in two
separate studies. Study one was a compar-
ison in healthy subjects comparing non-
smokers with smokers; study two was dou-
ble-blind comparison with diltiazem.
The article raises several issues that we
believe require clarification by the authors.
First, the article does not contain any data
on the diameter measurements. This is im-
portant, because previous studies2,3 that
TABLE 1. Comparison of postoperative morbidity and mortality in patients un-
dergoing bronchial sleeve resection (induction treatment versus no treatment)
Overall
(n  106)
Induction
(n  56)
No induction
(n  50)
P valueNo. % No. % No. %
Perioperative morbidity
Minor complications 29 27.5 12 21.4 17 34 .15
Major complications 7 6.6 5 8.9 2 4 .44
Late morbidity 6 5.6 3 5.3 3 6 .99
Perioperative mortality 5 4.7 2 3.6 3 6 .66
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used the same dose of vitamin C did not
show any acute effect on the baseline (un-
stimulated) diameter, at the same time
showing an improvement in endothelial va-
somotor function. Our own observations
are also consistent with this. By showing
an increase in the lumen surface area, de-
rived from diameter changes, Drossos and
colleagues1 implied that vitamin C pro-
duces endothelium-independent dilatation.
Second, Drossos and colleagues1 pre-
sented their data as lumen surface area.
Why was this chosen? Also, was it derived
from r2? This also was not made clear in
the article.
Third, the results were actually pre-
sented as percentage change of lumen sur-
face area. With this approach, any small
change in measured diameter would be
magnified by conversion to lumen surface
area and further magnified by analysis of
percentage change. Was the change in di-
ameter statistically significant?
Finally, despite the larger increase in
lumen surface area seen with vitamin C
than with diltiazem, there did not appear to
be any effect on blood pressure. Did Dros-
sos and colleagues1 see a change in heart
rate and blood pressure in the vitamin C
group? If not, why not?
Anil Madhavan, FRCS
Jonathan Goodfellow, FRCP
Wales Heart Research Institute
University of Wales College of Medicine
Cardiff, United Kingdom
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Reply to the Editor:
We thank Madhavan for his interest in our
work. We have addressed these issues as
follows, in reverse order:
We did not measure blood pressure and
heart rate in the vitamin C group because
we were unaware that this would be nec-
essary.1,2 We did measure just the blood
pressure before and 2 hours after the oral
administration of 2 g vitamin C in 6 vol-
unteers (2 smokers and 4 nonsmokers). We
found no change in arterial blood pressure
after the administration of 2 g vitamin C,
but the heart rate was reduced by 5% to
10% in 4 subjects (2 smokers and 2 non-
smokers). We recommend repetition of this
trial by others.
The changes in diameter of the radial
artery were statistically significant in all
four groups (Table 1). The mean percent-
age increases in radial diameter were
7.38% in the control group and 18.75% in
the smoking group (P  .004 when ana-
lyzed by t test or P  .004 when analyzed
by Mann-Whitney U test). Also, the mean
percentage increases in radial diameter was
15.88% in patients with coronary artery
disease who received vitamin C and 7.76%
in patients with coronary artery disease
who received diltiazem (P  .037 when
analyzed by t test or P  .016 when ana-
lyzed by Mann-Whitney U test).
Lumen surface area measurement was
chosen because the Acuson equipment that
we used exhibits it (Figure 1 in the original
article). With respect to not using the r2
formula, we assumed that all readers are
aware of the meaning of our statement:
“All lumen surface areas (derived from the
estimated lumen diameter) are expressed in
square millimeters” in the Methods section
of our article.
Diameter measurements from the orig-
inal data are given in Table 1 as desired by
Madhavan. As to the new findings in Greek
patients from a remote mountain region of
Epirus, on a typical Mediterranean diet,
without discontinuation of multiple medi-
cations before the administration of vita-
min C, and notably heavy smokers, it ap-
pears that vitamin C plus “something” does
indeed cause endothelium-independent va-
sodilation in the radial artery of our pa-
tients. In addition, the objective of our
work is to protect a vessel that is exces-
sively handled during harvesting for coro-
nary artery bypass grafting.3 Therefore our
study with ultrasonographic probing,
which may be excessive (as many as 5
minutes of manipulation of the radial ar-
tery) does not necessarily imply a systemic
effect. Perhaps the study may be furthered
by studying other populations and arter-
ies.4,5
Ioannis K. Toumpoulis, MD
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TABLE 1. Diameter (expressed in mm) of radial arteries (mean SD) at baseline
and 2 hours after the oral administration of 2 g vitamin C in four groups of 15
subjects each
Baseline
2 hr after
vitamin C
P value
(Wilcoxon
test)
Control subjects 3.60 0.50 3.85 0.50 .008
Smokers 3.36 0.33 3.96 0.30 .001
Coronary artery disease, vitamin C 3.57 0.49 4.14 0.65 .001
Coronary artery disease, diltiazem 3.58 0.46 3.83 0.38 .009
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